Better Longer-Term Survival in NSCLC After Nivolumab Response Better Longer-Term Survival in NSCLC After Nivolumab Response

Previously treated patients with advanced NSCLC who responded to nivolumab had long-term survival that was notably higher than patients who received docetaxel.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news